Philips Unveils Trilogy Evo Portable Vent at ERS 2018 in Paris

New portable ventilator builds on Philips respiratory clinical excellence to enhance transitional care coordination and collaboration

At the European Respiratory Society (ERS) International Congress 2018 in Paris, France (September 15-19), Royal Philips, will showcase the company’s growing portfolio of advanced connected care solutions designed to foster effective and efficient care for chronic respiratory and sleep conditions. During the show, Philips will also unveil its newest connected solution, Trilogy Evo, the only portable life support ventilator platform designed to stay with patients to provide consistent therapy and monitoring as they change care environments and when their condition changes.

Chronic conditions such as Chronic Obstructive Pulmonary
Disease (COPD) can be difficult to manage due to complex care plans, large care
teams, and frequent readmissions.  Integrated with Care
Orchestrator
, Philips’ sleep and respiratory care cloud-based
management system, Trilogy Evo will help to ease this burden by allowing physicians,
clinicians, and care providers to collaborate and coordinate care from hospital
to home by storing their patient prescription and therapy information in a
single secure location. 

“Worldwide, chronic conditions are on the rise, presenting continually growing care challenges. Time and again, we have seen the positive impact that connected care can have not only on patients but on the care teams that serve them,” said John Frank, Business Leader for Sleep and Respiratory Care at Philips. “With effective treatment options, chronic respiratory conditions can be managed effectively. Trilogy Evo is our next evolution of work in connected care solutions, making therapy management for chronic conditions easier and more efficient.”

Along with Trilogy Evo, Philips will showcase the latest
suite of integrated innovations in sleep and respiratory care including:

  • Care
    Orchestrator
    , Philips cloud-based patient management software
    solution that allows providers and clinicians to efficiently manage patient
    care across a single platform. Through its cloud-based solutions like Care
    Orchestrator, Philips enables the care of more than 8.5 million connected sleep
    and respiratory patients worldwide.
  • NightBalance Lunoa is the latest treatment for positional sleep
    apnea. The small, lightweight device worn in a belt around the chest uses
    gentle vibrations to help stop wearers from sleeping on their back. Over 73% of adults using the NightBalance Lunoa
    therapy reported a long-term improvement in the three most reported positional
    sleep apnea symptoms. [2]
  • SmartSleep,
    the world’s first and only clinically proven wearable solution for consumers to
    improve deep sleep quality for people who do not get enough sleep due to
    lifestyle. After two weeks of use, 70 percent of users in a clinical trial reported
    feeling less tired during the day. [3] Connectivity with the Smart Sleep mobile
    application offers users with direct access to sleep data and analysis.
  • Philips
    DreamWear line
    , including DreamWear
    Full Face
    , the
    newest option available for its award-winning sleep mask line that places the
    hose on top of the head instead of in front of the face, offering freedom of
    movement and the ability to sleep in any position. Users and technicians can
    easily swap cushions between DreamWear mask frames. CPAP users reported
    being more satisfied with fit and comfort of the DreamWear Full face mask over
    other leading full face masks. [4]
  • DreamStation
    Go
    , At half the size of our System One and DreamStation platforms,
    DreamStation Go offers the same therapy and comfort features used by over 5
    million CPAP users and 1/3 components to pack than its closest competitors.
  • DreamMapper,
    the #1 downloaded and top-rated PAP therapy engagement mobile and web-based application
    shown to enhance adherence. [5] 58 percent more people use their therapy every
    night when using DreamMapper. [6]

Additionally,Philips executives and partners
will participate in the following industry workshops during ERS 2018, sharing their
clinical insight into chronic sleep and respiratory conditions:

  • Industry
    Practical Workshop
    : Sunday, September 16, 13:15 – 14:30, Hall
    7.3 I L

    • “Advance monitoring for a next generation
      ventilator” hosted by Teofilo Lee-Chiong, MD; Chief Medical Liaison at Philips
      with speaker Cesare Gregoretti, MD.
  • Industry
    Practical Workshop:
    Monday, September 17, 13:15 – 14:30, Hall 7.3
    I L

    • “Expiratory Flow Limitation – What it is and
      Why it matters” featuring Dr. Peter Calverley

To experience the entire portfolio of sleep and respiratory products, visit Philips at ERS booth B06. For updates on Philips’ presence at ERS 2018 or more information on Philips’ advanced solutions for sleep and respiratory care, follow @PhilipsResp or visit Philips.com/At-ERS-Congress.

[1] Global Initiative for Chronic Obstructive Lung
Disease. 2017. Retrieved from: http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd

[2] Dutch
Apnea Society survey (Apneuvereniging) based on 75 NightBalance users for an
average of 2.2 years

Page 7, most reported symptoms, page 8, reported results by symptom, mean results of top 3 symptoms

[3] Home user trial 1 shows that 70% of chronically sleep-deprived participants rated their level of daytime sleepiness lower after 2 weeks than they did at baseline.

[4] Aug 2017
Patient Preference trial, n = 85; compared masks included Resmed Airfit F10 and
F20, Respironics Amara View and F&P Simplus

[5] Source: April
2018 review of Apple App Store®, Google Play™ store and App Annie™

[6] 19%
of DreamMapper users used their therapy 100% of the nights over 90-days versus
12% for the Standard Care users, a 58.33% increase. In a retrospective review conducted by Philips
Respironics of the EncoreAnywhere database that compared DreamMapper patients
(n=85,077) to users who did not use it (n=87,602).

Be the first to comment

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.